Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 6/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682122 | 0.85 | ADORA2A (0.38) | ADORA2AADORA1HDAC6CDK2CCNA2 | |
| SCHEMBL25936242 | 0.85 | ADORA2A (0.38) | ADORA2AADORA1HDAC6HDAC1LTA4H | |
| SCHEMBL145694 | 0.74 | HDAC6 (0.40) | ADORA2AADORA1HDAC6HDAC1ALDH1A1 | |
| SCHEMBL12362498 | 0.73 | HPGD (0.35) | SMN1; SMN2PI4KBHCAR3ALDH1A1MAPK14 | |
| SCHEMBL21311362 | 0.73 | ADA (0.36) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13044929 | 0.73 | HDAC6 (0.47) | ADORA2AADORA1HDAC6SMN1; SMN2CDK2 | |
| SCHEMBL28290150 | 0.72 | LTA4H (0.40) | HDAC6HDAC1MEN1ALDH1A1KMT2A | |
| SCHEMBL17807827 | 0.70 | HCAR3 (0.40) | ADORA2AADORA1SMN1; SMN2CDK2ADORA2B | |
| SCHEMBL17446062 | 0.70 | MET (0.50) | ADORA2AADORA1SMN1; SMN2DYRK1ACDK5 | |
| SCHEMBL30888970 | 0.70 | MET (0.50) | ADORA2AADORA1SMN1; SMN2DYRK1ACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885HDAC6 1189/4885 |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | ADORA2A 3011/4885ADORA1 3922/4885HDAC6 881/4885 |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | ADORA2A 885/4885ADORA1 1321/4885HDAC6 1093/4885 |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ADORA2A 900/4885ADORA1 2594/4885HDAC6 2216/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | ADORA2A 4258/4885ADORA1 4406/4885HDAC6 1419/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | ADORA2A 3011/4885ADORA1 3922/4885HDAC6 881/4885 |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | ADORA2A 118/4885ADORA1 32/4885HDAC6 3164/4885 |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | CALCB, BDKRB2, BDKRB1 | ADORA2A 273/4885ADORA1 80/4885HDAC6 3875/4885 |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ADORA2A 900/4885ADORA1 2594/4885HDAC6 2216/4885 |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | ADORA2A 104/4885ADORA1 18/4885HDAC6 3601/4885 |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ADORA2A 900/4885ADORA1 2594/4885HDAC6 2216/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ADORA2A 1481/4885ADORA1 2642/4885HDAC6 276/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | ADORA2A 355/4885ADORA1 1063/4885HDAC6 2987/4885 |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN3, NSUN2 | ADORA2A 1304/4885ADORA1 2452/4885HDAC6 3104/4885 |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | ADORA2A 355/4885ADORA1 1063/4885HDAC6 2987/4885 |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | ADORA2A 69/4885ADORA1 17/4885HDAC6 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.